

BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 23rd December 2024

COMMUNICATION- OTHER RELEVANT INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17th March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

During the Extraordinary General Meeting of Shareholders of FACEPHI BIOMETRÍA, S.A., held on 23rd December, at second call, with the attendance of a total of 17 shareholders, present or represented, and representing a total of 39,98% of the share capital, all the resolutions submitted to vote in accordance with the notice of the General Meeting published at the time were approved. The resolutions adopted are as follows:

FIRST: Capital increase by compensation of credits, consequently, without pre-emptive subscription rights, for an effective amount (par value plus premium) of 1.834.163,01 euros, by issuing and placing into circulation 1.126.837 ordinary shares of the Company, each with a par value of 0.04 euros. Amendment of Article 5 of the Company's Bylaws.

It's approved the increase of the social capital of Facephi Biometría, S.A., currently set at 971.388,36 €, to 1.016.461,84 €, that is to say, to increase it by 45.073,48 € by offsetting the credits that are detailed in the Board Report that has been made available to you together with the notice of this Extraordinary General Shareholders' Meeting. For this purpose, 1.126.837 ordinary registered shares, each with a par value of 0.04 Euro will be issued.

Article 5.- SHARE CAPITAL

The share capital is 1.016.461,84 euros, divided into 25.411.546 identical, accumulative and indivisible shares with a par value of € 0.04 each, all of the same class and numbered from 1 to 25.411.546.

SECOND: - Delegation of Powers

It was approved by majority to delegate to the Chairman and the Secretary of the Board all the necessary procedures to make the agreements reached public.

And with no further business to discuss, the minutes were approved by the attendees.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors